Intellia Therapeutics (NTLA) Change in Account Payables (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Change in Account Payables for 12 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables rose 24.02% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 1108.78% YoY), while the FY2025 annual figure was $6.0 million, down 11.96% from the prior year.
• Change in Account Payables fell to -$1.4 million in Q1 2026 per NTLA's latest filing, from $7.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $7.0 million in Q4 2025 and bottomed at -$7.7 million in Q3 2023.
• Historically, Change in Account Payables has averaged $547352.9 across 5 years, with a median of $750000.0 in 2022.
• On a YoY basis, Change in Account Payables climbed as much as 2152.63% in 2023 and fell as far as 374.51% in 2023.
• Intellia Therapeutics' Change in Account Payables stood at $750000.0 in 2022, then jumped by 425.47% to $3.9 million in 2023, then slumped by 63.56% to $1.4 million in 2024, then surged by 384.61% to $7.0 million in 2025, then plunged by 120.41% to -$1.4 million in 2026.
• Business Quant data shows NTLA's Change in Account Payables at -$1.4 million in Q1 2026, $7.0 million in Q4 2025, and $3.5 million in Q3 2025.